Related Experiment Video
Updated: May 3, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.1K
Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis - A Comprehensive Literature
Sukainah Ahmed Al Alshaikh1, Zahra Mohammad Almarhoon1, Hisham Momattin1
1Department of Pharmacy, Mouwasat Hospital, Dammam, Saudi Arabia.
Psoriasis (Auckland, N.Z.)
|August 11, 2025
Summary
Bimekizumab, a dual inhibitor of IL-17A and IL-17F, offers superior efficacy and rapid response for plaque psoriasis treatment compared to other biologics. It provides better skin clearance with a comparable safety profile.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Psoriasis is a chronic immune-mediated disease affecting 1-3% globally.
- Interleukin IL-17A and IL-17F play key roles in psoriasis pathophysiology.
- Dual neutralization of IL-17A and IL-17F may enhance treatment efficacy.
Purpose of the Study:
- To evaluate the efficacy and safety of bimekizumab in treating plaque psoriasis.
- To compare bimekizumab's performance against placebo and existing biologics.
- To assess bimekizumab's potential to improve treatment outcomes in plaque psoriasis management.
Main Methods:
- Four randomized controlled trials (RCTs) involving approximately 2,200 patients with plaque psoriasis.
- Bimekizumab selectively targets and neutralizes both IL-17A and IL-17F.
- Efficacy measured by PASI 90 and PASI 100 response rates at 16 weeks.
Main Results:
- Bimekizumab demonstrated superior efficacy compared to placebo, adalimumab, secukinumab, and ustekinumab.
- Higher rates of PASI 90 and PASI 100 were achieved with bimekizumab at 16 weeks.
- Bimekizumab showed a rapid onset of action and comparable safety profile, with common adverse events including oral candidiasis and upper respiratory tract infections.
Conclusions:
- Bimekizumab offers significant advantages in treating plaque psoriasis, including enhanced efficacy and rapid response.
- Its dual inhibition of IL-17A and IL-17F provides superior outcomes.
- Bimekizumab represents a promising option for psoriasis treatment algorithms, potentially improving patient outcomes.
Related Concept Videos
01:21EPS and iPS Cells in Disease Research
3.2K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K